Welcome to our dedicated page for Strata Skin Sciences SEC filings (Ticker: SSKN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The STRATA Skin Sciences, Inc. (NASDAQ: SSKN) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing a structured view of how this medical technology issuer reports its operations, governance, and capital activities. As a Nasdaq-listed manufacturer of in-office dermatologic devices such as the XTRAC® excimer laser, VTRAC® lamp systems, and TheraClearX® Acne Therapy System, STRATA uses its SEC filings to detail financial performance, risk factors, reimbursement developments, and strategic initiatives.
Core periodic reports like the Form 10-K annual report and Form 10-Q quarterly reports contain audited and interim financial statements, segment information for dermatology recurring procedures and equipment, and management’s discussion of trends in recurring billings, equipment revenue, and margins. These filings also discuss dependencies on reimbursement under CPT® codes 96920–96922 for excimer laser procedures and outline key risks related to payer policies, clinical adoption, and competition in dermatology devices.
Current reports on Form 8-K provide more immediate insight into material events. STRATA has filed 8-Ks to announce quarterly financial results, registered direct offerings, at-the-market equity distribution arrangements, Nasdaq listing compliance notices, and investor presentations. These filings give context on capital raising activities, stockholders’ equity levels, and the company’s responses to Nasdaq’s continued listing requirements.
The company’s proxy statement on Form DEF 14A offers additional detail on corporate governance, director elections, equity incentive plans, and the selection of the independent registered public accounting firm. For investors tracking executive compensation structures, board oversight, and shareholder voting matters, the proxy materials are a primary reference.
On Stock Titan, users can access these STRATA filings alongside AI-powered summaries that highlight key points from lengthy documents, such as revenue composition, non-GAAP measures like adjusted EBITDA, and updates on reimbursement or litigation. The platform also surfaces real-time 8-Ks and other new submissions from EDGAR, helping users follow developments such as financing transactions, regulatory notices, and strategic disclosures without reading every page manually.
For those interested in trading dynamics and governance, Form 4 insider transaction reports and related ownership disclosures, when available, can be reviewed to see how STRATA’s officers, directors, or significant shareholders are transacting in SSKN shares. Together, these filings provide a detailed regulatory record of STRATA Skin Sciences’ financial condition, strategic direction, and compliance as a public dermatology device company.
Strata Skin Sciences, Inc. filed a Form 25 notifying the removal of its Common Stock, $0.001 par value from The Nasdaq Stock Market LLC. The filing states the Exchange and the issuer have each complied with the procedures set forth in 17 CFR 240.12d2-2. The notice is dated
Strata Skin Sciences, Inc. plans to delist its common stock from Nasdaq and terminate its SEC reporting obligations after failing to regain compliance with Nasdaq’s minimum $2.5 million stockholders’ equity requirement. Nasdaq has notified the company that trading is expected to be suspended at the opening on February 19, 2026.
The company anticipates filing a Form 25 around February 19, 2026 to deregister under Section 12(b), followed by a Form 15 around March 2, 2026 to begin “going dark” under Sections 12(g), 13(a) and 15(d). Management and the board cite expected time and cost savings, but acknowledge that delisting and going dark will likely make the stock more illiquid and harder for stockholders to sell.
Strata Skin Sciences, Inc. furnished a new investor presentation, dated December 2025, for investors and analysts. The company posted this presentation on its website and attached it as Exhibit 99.1 to a current report. The material is provided under a section that means it is being furnished, not filed, so it is not subject to certain liability provisions and will only be incorporated into other documents if specifically referenced.